anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adult participants with a diagnosis of MM who received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
BACKGROUND: The timing of trans-anal endorectal pull-through (TAEPT) for Hirschsprung's disease (HD) is controversial. Early endorectal pull-through avoids the occurrence of preoperative enterocolitis. However, delayed pull-through (≥31 days) enables postnatal maturation of the anal canal and sphincter complex. The aim of this study was to identify the best age to perform trans-anal pull-through according to the literature.
METHODS: This is a comprehensive systematic review. All articles published from 2010 to 2022 were searched in the Web of Science, Ovid Medline, PubMed, CINAHIL, and Embase databases, using the keywords HD, delayed or early treatment, trans-anal pull-through surgery, age, sex or gender, complications and outcomes. Articles that met the inclusion criteria with good to fair quality according to the Newcastle-Ottawa quality assessment and low bias score in the Cochran collaboration tool were reviewed.
RESULTS: Sixteen studies were eligible to be reviewed. The overall results of this study showed that due to more common short-term complications at neonatal period and lower contrast enema diagnostic accuracy in determining the transition zone, it seems to be reasonable decision to postpone surgery until the child is several months old. There was also no difference in terms of complications and outcomes of trans-anal pull-through surgery between females and males.
CONCLUSION: It is not recommended to delay surgery too much for ages over 1 year. Ages between 3 and 12 months can be a good time for interventional treatment for HD.
Longitudinal Evaluation of the Efficacy and Safety of Divalproex and Lithium in Dual Diagnosis Bipolar Rapid Cycling: This study recruits males and females age 18 and older who currently meet diagnostic criteria for rapid cycling bipolar disorder (type I or II) and who have met the criteria for substance abuse or dependence of cocaine, marijuana and/or alcohol within the past six months. Patients are initially stabilized on dual therapy of lithium and depakote and then randomly assigned to double-blind treatment with either lithium monotherapy or continued dual therapy. Patients remain in the study for six months or until they experience a relapse. Patients in this study are required to bring a friend or family member to all study visits as well as attend chemical dependency services. This study is sponsored by the NIMH. Subjects receive study-related care at no cost.
<P>PROBLEM TO BE SOLVED: To provide a fusion protein of antibody or antigen, maintaining a natural heterodimeric structure of heterodimeric cytokine and cytokine, and its production method.  <P>SOLUTION: A heterodimeric fusion protein is provided, which contains the first and second chimera chains. The first chimera chain contains a part of an Ig heavy chain connected to the first subunit of a heterodimer cytokine by a peptide bond. The second chimera chain contains a part of an Ig heavy chain connected to the second subunit of the heterodimer cytokine by a peptide bond. The first and second chains are linked by a disulfide bond.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The current invention relates to a gargle dosage formulation and a method for removing the bitter taste in oral medication or food. Particularly, this bitter-removal formulation comprises at least one of two preparations, the first preparation and the second preparation. The current invention also discloses a method of using the preparations before and after taking oral medication or food. Right before taking oral medication or food, the first preparation is used to gargle the user's oral cavity. After it is spat out, the first preparation forms a thin layer on the surface of the oral mucosa to cover, shield, and protect taste buds from the direct contact with oral medication or food. Immediately after oral medication or food is taken, the second preparation is used to gargle and clean the user's taste buds, which effectively elutes mucosa-binding bitter ingredients from the oral cavity. Because both preparations are spat out, there is neither body intake of these preparations nor interference to the oral medication. The gargle preparation can be generally used with various types of oral medication. Both preparations in this formulation are simple, safe, inexpensive, and easy to use. The first and second preparations may be used together or only one of them is used. The gargle preparation is very effective to minimize and remove tastes such as the bitter taste, peculiar taste, and dulled taste, which are associated with the traditional herbal medicine such as traditional Chinese herbs and their decoctions. The gargle preparation helps patients who are taking oral medication with the bitter taste to maintain healthy taste buds and improve life quality.
BACKGROUND: Glioblastoma (GBM) brain tumors lacking IDH1 mutations (IDHwt) have the worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but tumors almost always fatally recur.
RESULTS: Using RNA sequencing data from 107 pairs of pre- and post-standard treatment locally recurrent IDHwt GBM tumors, we identify two responder subtypes based on longitudinal changes in gene expression. In two thirds of patients, a specific subset of genes is upregulated from primary to recurrence (Up responders), and in one third, the same genes are downregulated (Down responders), specifically in neoplastic cells. Characterization of the responder subtypes indicates subtype-specific adaptive treatment resistance mechanisms that are associated with distinct changes in the tumor microenvironment. In Up responders, recurrent tumors are enriched in quiescent proneural GBM stem cells and differentiated neoplastic cells, with increased interaction with the surrounding normal brain and neurotransmitter signaling, whereas Down responders commonly undergo mesenchymal transition. ChIP-sequencing data from longitudinal GBM tumors suggests that the observed transcriptional reprogramming could be driven by Polycomb-based chromatin remodeling rather than DNA methylation.
CONCLUSIONS: We show that the responder subtype is cancer-cell intrinsic, recapitulated in in vitro GBM cell models, and influenced by the presence of the tumor microenvironment. Stratifying GBM tumors by responder subtype may lead to more effective treatment.
FIELD: medicine. SUBSTANCE: invention relates to method of preparing solutions for hemodialysis used in medicinal practice in devices "artificial kidney" in preparing patients for transplantation of organs, in infectious and reanimation departments. Inorganic salts CaCl 2 •6H 2 O and MgCl 2 •6H 2 O are dissolved in purified water separately from salts NaCl, KCl and CH 3 COONa•3H 2 O and salts NaCl, KCl and CH 3 COONa•3H 2 O are dissolved at 80-90 C followed by their cooling. The solution containing salts CaCl 2 •6H 2 O and MgCl 2 •6H 2 O and solution containing salts NaCl, CH 3 COONa•3H 2 O and KCl are mixed at temperature 20-25 C. Invention provides standardization and stability of ionic composition of blood to be purified due to enhancement of uniformity of the concentrated solution composition and time reduction of its preparing. EFFECT: improved method of preparing. 4 tbl, 4 ex
Kidney transplantation is the best treatment option for patients with end-stage renal disease owing to improved survival and quality of life compared with dialysis. The surgical approach to kidney transplantation has been somewhat stagnant in the past 50 years, with the open approach being the only available option. In this scenario, evidence of reduced surgery-related morbidity after the introduction of robotics into several surgical fields has induced surgeons to consider robot-assisted kidney transplantation (RAKT) as an alternative approach to these fragile and immunocompromised patients. Since 2014, when the RAKT technique was standardized thanks to the pioneering collaboration between the Vattikuti Urology Institute and the Medanta hospital (Vattikuti Urology Institute-Medanta), several centres worldwide implemented RAKT programmes, providing interesting results regarding the safety and feasibility of this procedure. However, RAKT is still considered an alternative procedure to be offered mainly in the living donor setting, owing to various possible drawbacks such as prolonged rewarming time, demanding learning curve, and difficulties in carrying out this procedure in challenging scenarios (such as patients with obesity, severe atherosclerosis of the iliac vessels, deceased donor setting, or paediatric recipients). Nevertheless, the refinement of robotic platforms through the implementation of novel technologies as well as the encouraging results from multicentre collaborations under the umbrella of the European Association of Urology Robotic Urology Section are currently expanding the boundaries of RAKT, making this surgical procedure a real alternative to the open approach.
Kidney Transplant Recipients at the University of Minnesota since 1984. The study looks at a 10 year followup of steroid-free maintenance immunosuppression, post-transplant infections and evaluation of the DGF nomogram in Thymoglobulin on patients at the University of Minnesota.
Ceftriaxone infusion. Ceftriaxone is a beta-lactam antibiotic that is the standard-of-care antibiotic for prophylaxis of asymptomatic bacteriuria in Switzerland. The choice of 2000 mg delivered intravenously reflects the general practice.
BACKGROUND/AIMS: The corona virus disease 2019 posed a major risk for end-stage kidney disease (ESKD) cases. Our study aimed to assess changes in kidney replacement therapy (KRT) trends and healthcare access for these patients during the pandemic.
METHODS: We retrospectively analyzed nationwide data from July 2017 to June 2022 to assess changes in KRT and ESKD incidence. KRT modalities included peritoneal dialysis (PD), hemodialysis (HD), and kidney transplantation (KT). We utilized the interrupted time series (ITS) method to compare changes in KRT modality before and after the incidence of the COVID-19 pandemic.
RESULTS: ESKD incidence remained stable from 2018 to April 2022. The ITS analysis confirmed that the pandemic did not significant impact overall KRT incidence. PD cases decreased (5.7% to 1.3%), while HD cases increased (81.6% to 85%), and KT recipient remained relatively stable (12.7% to 17.3%). The hospitalization and hospital stay decreased in nursing hospital (165.01 days to 147.77 days) and general hospital (61.34 days to 55.58 days) during the pandemic, however, remained unchanged for PD and KT.
CONCLUSION: Our findings indicate no significant changes in ESKD incidence in South Korea during the pandemic. However, there were shifts in modality distribution, with decreased PD and increased HD cases. Notably, HD cases showed a significant reduction in hospital admissions and length of stay. The healthcare system demonstrated stability during the pandemic, with minimal disruptions in ESKD care.
INTRODUCTION: Patients with chronic inflammatory skin diseases often suffer from sleep disturbances. However, objective data on sleep architecture, especially to evaluate potential overall influences under therapy, are lacking.
PATIENTS AND METHODS: Pilot study on sleep quality changes including psoriasis and atopic dermatitis patients before and 2 weeks after intensive topical treatment. In addition to disease activity rating, patient-rated outcomes for itch severity and sleep quality and polygraphy was performed before and after topical therapy.
RESULTS: 14 psoriasis, eleven atopic dermatitis patients (10 female, 15 male) with a mean age of 49 years were included. Disease activity scores (EASI and PASI) were significantly reduced with topical therapy after 2 weeks (p < 0.001). Pruritus intensity (NRS) showed a significant influence on deep sleep, which resolved after therapy. Insomnia severity significantly decreased (r > 0.50, p < 0.05) and daytime sleepiness showed a significant reduction in 40% of patients. N3 (deep sleep) and REM sleep significantly improved, showing a strong effect (r > 0.50). The apnea-hypopnea index decreased in one of four patients independent of the individual BMI.
CONCLUSIONS: Through polygraphy, we demonstrated impaired sleep patterns in psoriasis and atopic dermatitis patients with itch as a relevant factor and beyond that, rapid sleep improvement under 2 weeks of topical treatment.
PURPOSE:A hair treatment effective for preventing and treating poliosis, with great safety, capable of taking part in melanin formation in hair roots, comprising  squalane as an active constituent. CONSTITUTION:A hair treatment comprising (A) 5vol% or more, preferably 5-10 vol%, of squalane and (B) an agent, e.g. an oily hair conditioner or shampoo. The effective amount of the treatment is about 100-500mg calculated as squalane, and its use once a day is sufficient for preventing poliosis. The mechanism of its action is considered to be the inactivation of SH groups in sulfur-containing amino acids in hair roots. The SH groups having the tyrosinase inhibitory action are believed to accelerate the melanin formation.
The invention belongs to the technical field of biology, and particularly relates to a recombinant erysipelothrix rhusiopathiae surface protection antigen A (surface protective antigen A, spaA) with tandem dominant epitopes and application thereof. The amino acid sequence of the recombinant erysipelas bacillus Sus surface protection antigen A of the tandem dominant epitope is shown as SEQ ID No.1, and the nucleotide sequence of the coded protein is shown as SEQ ID No.2. The invention further constructs an expression vector containing the nucleotide sequence, and the sequence is shown as SEQ ID No. 3. And (3) transforming escherichia coli to obtain a recombinant expression strain. The recombinant erysipelothrix rhusiopathiae surface protection antigen A with the tandem dominant epitope is uniformly mixed with the adjuvant, so that an immune response can be induced by an organism after a mouse is immunized, and 100% immune protection effect for resisting 1000MLD virulent attack can be provided for the virus-challenged mouse; after immunization of pigs, 67% of immune protection against 2MLD virulent attack can be provided for the challenged pigs, and 100% of immune protection against 1MLD virulent attack can be provided for the challenged pigs.
Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. Oral anticoagulation (OAC) is very effective for stroke reduction, but despite this treatment, AF patients with stroke in the past year still have a very high risk of recurrent stroke which is often disabling; estimated to be between 3 and 7% per year. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO). Thus, there is a well-documented unmet medical need to improve stroke reduction therapy for AF patients with prior ischemic stroke. This study aims to address this unmet need by testing whether use of bilateral carotid filter implants in addition to OAC will reduce the risk of stroke in AF patients with recent (e.g. within 12 months) ischemic stroke. These filters have been shown, in vitro, to capture all emboli ≥1.4 mm in length or diameter and additionally to capture some emboli of smaller diameter. Once placed bilaterally in the common carotid arteries, they are expected to prevent most emboli ≥1.4 mm in length or diameter and potentially some smaller ones from reaching the anterior cerebral circulation. Although the posterior circulation will not be protected, the majority of all large ischemic strokes in patients with AF occur in the anterior circulation (about 90%). It is hypothesized therefore that bilateral carotid implants will greatly reduce embolic strokes due to LVO (60% reduction) and will have an important but smaller effect on embolic strokes due to smaller emboli which cause non-LVO occlusion (10% reduction). LVO-associated strokes are more often large and disabling compared to non-LVO strokes. The primary goal of the study is to show that bilateral carotid implants reduce strokes due to LVO and that there is also a reduction in total ischemic stroke, both in comparison to a control arm (treatment with OAC only). The study will also evaluate the safety of the intervention.
Liver transplantation is the transplantation of the liver, which is completely or partially removed by surgical intervention, from a living or brain-dead cadaver to the recipient. Today, organ transplantation procedures are carried out successfully in many centers in our country.Liver transplantation has become the most effective treatment method for acute and chronic liver failure due to different reasons.The life expectancy of individuals with advanced liver disease, which was limited to months before liver transplantation, was extended with liver transplantation and the quality of life was improved with this treatment method. However, since most of the organ transplants are made from genetically different donors, tissue compatibility between the donor and the recipient remains a problem.Therefore, the recipient's immune response to donor graft antigens should be considered.

In recent years, the application of advanced surgery and new immunosuppressive approaches has made it possible to successfully transplant almost any vital organ or tissue. However, due to both infection and genetic factors, an immune response to the donor organ may develop and cause organ rejection. At this point, we think that early diagnosis and discovery of immune response parameters that distinguish infection from rejection may be important.In our study, some inflammatory Interleukin-2 , Interleukin-6, Interferon-γ, Tumor Necrosis Factor-α and anti-inflammatory Interleukin-4 and Interleukin-10 cytokine genes expressions and Triggering Receptor Expressed on Myeloid Cells-1, which contributes to the pathology of acute and chronic inflammatory diseases; Human Leukocyte Antigen-G5, which suppresses the immune response; the expression levels of transcription factor Forkhead box-P3 expressed in regulatory T-lymphocytes and Cluster of Differentiation (CD)14 genes, which are thought to be biomarkers in various infectious diseases and expressed in monocytes, will be measured from peripheral blood samples obtained from liver transplant patients before, 1 month and 6 months after the operation. In addition, the classical liver markers Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Platelet Count (PLT), Alpha Feto Protein (AFP), Direct Bilirubin (Bilirubin D), Total Bilirubin (Bilirubin T) and C- Levels of biochemical parameters such as Reactive Protein (CRP) will be measured. In the light of the data to be obtained, it is aimed to find biomarkers with high predictive value for rejection and infection after liver transplantation.
A foetal monitor includes a sensing device for measuring uterine movement and foetal heart rate of a patient under observation.      A data collection device is coupled to the sensing device and is arranged to receive and sample an output signal of the sensing device and to generate digital signals representative of at least foetal heart rate over a predetermined time interval. The monitor also includes data analysis means including recognition means operable periodically to calculate a baseline heart rate value by calculating a plurality of modal values for a respective plurality of modal ranges of the measured feotal heart rate over a predetermined time interval of the foetal heart rate and to recognize in the digital signals received over a signal link from the data collection device a plurality of predetermined information features by automatically analyzing the digital signals in relation to the baseline heart rate value, and classification means for classifying at least one of the features to produce first output signals representative of the existence of such features and representative of feature classifications. Signal storage means receives and stores the first output signals as a short term knowledge base. Database storage means is providing for storing reference data as a long term knowledge base. The monitor also includes an interference engine arranged to process signals representative of the short term and long term knowledge bases automatically to produce conclusion signals, and indication means arranged to receive the conclusion signals and provide an indication of the conclusion signals.
A vaccine that interrupts malaria transmission is critical to eradicate the disease, but improved assays are needed to measure the efficacy of vaccines. Transmission-blocking vaccines (TBVs) work by inducing antibodies in vaccines that inhibit parasite development in the mosquito interrupting transmission. Efficacy of vaccines may be estimated by in vitro membrane feeding assays using immune sera and laboratory mosquitoes, but qualified assays that measure transmission in the field are needed to assess transmission-blocking interventions in natura. Clinical trials of TBV have started elsewhere on the continent in Mali, and we expect to expand TBV studies here in Burkina Faso in the future. This protocol will use a longitudinal cohort to gather information on the rates of blood smear positive individuals by month, season and year at Sabou Health district area, Burkina Faso. Individuals in the villages will be approached first for participation, including permission to contact their household and neighbors of their compound for participation. Households will be identified using census data and individuals will be consented for participation. Malaria smears will be obtained at monthly visits, in conjunction with mosquito collections in/around village residences. Parasite rates in locally caught mosquitoes will be assessed longitudinally for differences by season and year.

A total of 600 volunteers from Sabou area will be enrolled. Participants aged 0.5-65 years will have monthly blood sampling and mosquito collection at their household. Participants will be followed for up to 1 year, to collect data that will guide the design of future community-based trials of TBV.